Next Article in Journal
Development of a Column-Switching HPLC-MS/MS Method and Clinical Application for Determination of Ethyl Glucuronide in Hair in Conjunction with AUDIT for Detecting High-Risk Alcohol Consumption
Next Article in Special Issue
Stabilization of the CD81 Large Extracellular Loop with De Novo Disulfide Bonds Improves Its Amenability for Peptide Grafting
Previous Article in Journal
Buspirone Nanovesicular Nasal System for Non-Hormonal Hot Flushes Treatment
Previous Article in Special Issue
In Silico Structural Evaluation of Short Cationic Antimicrobial Peptides
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Pharmaceutics 2018, 10(3), 83; https://doi.org/10.3390/pharmaceutics10030083

Overview of Antibody Drug Delivery

1
UCL School of Pharmacy, London WC1N 1AX, UK
2
National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1 V9EL, UK
*
Author to whom correspondence should be addressed.
Received: 27 March 2018 / Revised: 29 June 2018 / Accepted: 29 June 2018 / Published: 4 July 2018
(This article belongs to the Special Issue Protein Therapeutics)
Full-Text   |   PDF [1368 KB, uploaded 4 July 2018]   |  

Abstract

Monoclonal antibodies (mAbs) are one of the most important classes of therapeutic proteins, which are used to treat a wide number of diseases (e.g., oncology, inflammation and autoimmune diseases). Monoclonal antibody technologies are continuing to evolve to develop medicines with increasingly improved safety profiles, with the identification of new drug targets being one key barrier for new antibody development. There are many opportunities for developing antibody formulations for better patient compliance, cost savings and lifecycle management, e.g., subcutaneous formulations. However, mAb-based medicines also have limitations that impact their clinical use; the most prominent challenges are their short pharmacokinetic properties and stability issues during manufacturing, transport and storage that can lead to aggregation and protein denaturation. The development of long acting protein formulations must maintain protein stability and be able to deliver a large enough dose over a prolonged period. Many strategies are being pursued to improve the formulation and dosage forms of antibodies to improve efficacy and to increase the range of applications for the clinical use of mAbs. View Full-Text
Keywords: antibodies; protein; pharmacokinetics; drug delivery; stability antibodies; protein; pharmacokinetics; drug delivery; stability
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Awwad, S.; Angkawinitwong, U. Overview of Antibody Drug Delivery. Pharmaceutics 2018, 10, 83.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top